Related Experiment Videos
Modulation in vitro of H-ras oncogene expression by trans-splicing
C Codony1, S Guil, C Caudevilla
1IIBB-CSIC (Instituto de Investigaciones Biomédicas de Barcelona-Consejo Superior de Investigaciones Científicas), Dept. PMT, Unidad de Biología y Farmacología Molecular del Cáncer, c/Jorge Girona Salgado 18-26, 08034 Barcelona, Spain.
Oncogene
|July 6, 2001
Summary
Researchers modulated pre-mRNA processing using trans-splicing to create p19 RNA, potentially offering a less tumorigenic alternative to H-ras oncogene activation in cancer therapy.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- Activated N-, K-, and H-ras oncogenes are implicated in approximately 30% of human solid tumors.
- Alternative splicing of c-H-ras pre-mRNA via the IDX exon produces p19 mRNA, a pathway suggested to be less tumorigenic than p21 activation.
Purpose of the Study:
- To utilize mammalian trans-splicing to modulate H-ras pre-mRNA processing.
- To generate mRNA similar to mature p19 RNA, exploring a potentially less oncogenic pathway.
Main Methods:
- Employing a mammalian trans-splicing mechanism to target the E4A exon of the H-ras gene.
- Reprogramming rat carnitine octanoyltransferase exon 2 to interact with the H-ras terminal region.
- Assessing trans-splicing efficiency in competition with endogenous cis-splicing.
Main Results:
- Demonstrated successful trans-splicing with a reprogrammed exon, producing the desired trans-splicing product.
- Observed concurrent down-modulation of the D intron's cis-splicing.
- Showed that human c-H-ras exon 4A can undergo successive trans-splicing events with external exons.
Conclusions:
- Mammalian trans-splicing is a viable tool for modulating H-ras pre-mRNA processing.
- This approach can generate p19 RNA, offering a potential therapeutic strategy against H-ras-driven tumors.
- Further research into trans-splicing could lead to novel cancer treatments targeting oncogene pathways.